[The Berlipril and Retalzem treatment of hypertension patients: the dynamics of the clinico-hemodynamic indices and of the vasodilating humoral factors].
Submitted in the paper are data on clinical, hemodynamic, and neurohumoral effects of monotherapy with an inhibitor of the angiotensin-converting enzyme berlipril (enalapril maleate) and a calcium antagonist of the benzothiazepine series retalzem (diltiazem resinate) versus their combination therapy. The combination therapy offers a number of important advantages over monotherapy with the above-named agents, consisting in apparent hypotensive action and a greater activation of endothelium-derived vasodilating and antiaggregation substances.